• Truemeds raised $85M led by Accel, valuing the company at $400M+ as it scales its generic medicine and diagnostics platform.
  • The startup helps chronic patients save up to 47% with technology-driven drug substitutions, serving 500,000 monthly users.
  • Expansion plans include AI-powered consultations, tier-2 city diagnostics, and tripling its fulfilment centres.

Mumbai-based Truemeds has secured $85 million in fresh funding led by Accel, with Peak XV Partners, WestBridge Capital, and InfoEdge Ventures also investing, propelling its valuation to over $400 million—almost four times its last round.

Founded in 2019, Truemeds chose to focus on affordable generic medicines rather than joining the crowded rush for fast delivery and branded discounts in India’s online pharmacy sector.

This strategy has proven effective for the country’s vast population of chronic patients, with over 400 million requiring regular medication.

The startup grew revenue 66% in the past year to ₹5 billion ($57 million), retaining over half its revenue after 12 months and serving an average 500,000 monthly customers—mostly in tier-2 cities—and more than 3 million total to date.

Truemeds recommends generic substitutes for branded prescriptions, helping the average user save 47% on their medicine bills last year, thanks to deep procurement relationships and technology-driven production planning with pharma manufacturers.

Rather than competing for the fastest delivery, Truemeds prioritises planned purchases and passes higher discounts to consumers, while promising four-hour delivery in major cities and using low-cost logistics elsewhere.

Next, the company is developing AI tools for customised consultations and launching doorstep diagnostics via lab partnerships.

Plans also include expanding fulfilment centres from 19 to nearly 60 and dedicating 20% of capital to engineering as it opens a new Bengaluru office.

With a workforce of 2,800, Truemeds remains focused on affordable healthcare, aiming to disrupt both the medicine and diagnostics markets for India’s underserved patients.

Edited by Annette George